Qiagen NV (NYSE:QGEN)’s share price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $39.75 and last traded at $39.75, with a volume of 15197 shares. The stock had previously closed at $39.35.

A number of equities analysts have issued reports on the company. UBS Group assumed coverage on Qiagen in a report on Friday. They issued a “neutral” rating for the company. Deutsche Bank reiterated a “buy” rating on shares of Qiagen in a report on Tuesday, January 29th. Finally, Jefferies Financial Group reiterated a “neutral” rating on shares of Qiagen in a report on Monday, January 21st. Eight analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $41.00.

The company has a debt-to-equity ratio of 0.63, a current ratio of 2.22 and a quick ratio of 2.05. The firm has a market cap of $8.87 billion, a price-to-earnings ratio of 29.69, a price-to-earnings-growth ratio of 2.45 and a beta of 0.91.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Monday, February 4th. The company reported $0.40 earnings per share for the quarter, meeting the consensus estimate of $0.40. Qiagen had a return on equity of 12.15% and a net margin of 12.68%. The firm had revenue of $403.20 million during the quarter, compared to the consensus estimate of $409.32 million. During the same period last year, the company earned $0.43 earnings per share. The company’s revenue was up 1.6% on a year-over-year basis. As a group, equities analysts forecast that Qiagen NV will post 1.45 EPS for the current fiscal year.

Several large investors have recently modified their holdings of QGEN. Vanguard Group Inc increased its holdings in shares of Qiagen by 2.0% during the third quarter. Vanguard Group Inc now owns 6,627,163 shares of the company’s stock valued at $251,037,000 after acquiring an additional 128,125 shares in the last quarter. Morgan Stanley increased its holdings in shares of Qiagen by 16.3% during the third quarter. Morgan Stanley now owns 1,468,052 shares of the company’s stock valued at $55,611,000 after acquiring an additional 205,698 shares in the last quarter. State of Alaska Department of Revenue increased its holdings in shares of Qiagen by 2.0% during the fourth quarter. State of Alaska Department of Revenue now owns 23,547 shares of the company’s stock valued at $811,000 after acquiring an additional 463 shares in the last quarter. Quadrant Capital Group LLC increased its holdings in shares of Qiagen by 104.5% during the fourth quarter. Quadrant Capital Group LLC now owns 6,923 shares of the company’s stock valued at $229,000 after acquiring an additional 3,538 shares in the last quarter. Finally, Advisors Capital Management LLC bought a new position in shares of Qiagen during the fourth quarter valued at $272,000. Hedge funds and other institutional investors own 64.00% of the company’s stock.

WARNING: “Qiagen (QGEN) Sets New 1-Year High at $39.75” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://theolympiareport.com/2019/03/15/qiagen-qgen-sets-new-1-year-high-at-39-75.html.

Qiagen Company Profile (NYSE:QGEN)

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Featured Story: How Do You Make Money With Penny Stocks?

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.